AstraZeneca pledges £300m UK life-science investment after stalling projects. Swedish-British pharma giant, HQ Cambridge. #bioeconomy
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
A roundup of recent cancer breakthroughs highlights new immunotherapies, targeted drugs and surgical-sparing treatments. The Independent reports on Scolyer’s pioneering work and a landmark NICE decision; The Guardian covers durvalumab’s promise in bladder cancer; Business Insider UK and Reuters summarize ASCO findings on pancreatic and colon cancers, among others.